cisplatin accord 1 mg/ml koncentrat za raztopino za infundiranje
accord healthcare - cisplatin - koncentrat za raztopino za infundiranje - cisplatin 1 mg / 1 ml - cisplatin
cisplatin accord 1 mg/ml koncentrat za raztopino za infundiranje
accord healthcare - cisplatin - koncentrat za raztopino za infundiranje - cisplatin 1 mg / 1 ml - cisplatin
cisplatin accord 1 mg/ml koncentrat za raztopino za infundiranje
accord healthcare - cisplatin - koncentrat za raztopino za infundiranje - cisplatin 1 mg / 1 ml - cisplatin
cisplatin hospira 1 mg/ml koncentrat za raztopino za infundiranje
hospira uk ltd. - cisplatin - koncentrat za raztopino za infundiranje - cisplatin 1 mg / 1 ml - cisplatin
cisplatin hospira 0,5 mg/ml koncentrat za raztopino za infundiranje
hospira uk ltd. - cisplatin - koncentrat za raztopino za infundiranje - cisplatin 0,5 mg / 1 ml - cisplatin
ofost 10 i.e./ml raztopina za injiciranje/infundiranje
oksitocin - raztopina za injiciranje/infundiranje - oksitocin 10 i.e. / 1 ml - oksitocin
ofost 10 i.e./ml raztopina za injiciranje/infundiranje
oksitocin - raztopina za injiciranje/infundiranje - oksitocin 10 i.e. / 1 ml - oksitocin
ofost 5 i.e./ml raztopina za injiciranje/infundiranje
oksitocin - raztopina za injiciranje/infundiranje - oksitocin 5 i.e. / 1 ml - oksitocin
lunsumio
roche registration gmbh - mosunetuzumab - limfom, folikularni - antineoplastic agents, monoclonal antibodies - lunsumio as monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (fl) who have received at least two prior systemic therapies.
tecvayli
janssen-cilag international n.v. - teclistamab - multiple myeloma - antineoplastična sredstva - tecvayli is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.